| |
Centre for Policy on Ageing | |
 | |
|
| The economic consequences of Alzheimer's disease in the context of new drug developments | | Author(s) | Martin Knapp, David Wilkinson, Rachel Wigglesworth |
| Journal title | International Journal of Geriatric Psychiatry, vol 13, no 8, August 1998 |
| Pages | pp 531-543 |
| Keywords | Dementia ; Drugs ; Costs [care] ; United Kingdom. |
| Annotation | The first national symptomatic treatment for Alzheimer's disease (AD) has received a very mixed reception from purchasers of health care in the UK. This is largely because detailed information on the long-term effects of this class of drugs is scarce. However, by looking at published evidence on the economic burden of Alzheimer's disease, some observations and assumptions can be made as to the influence of the new drug treatments. The drug therapies available and those most likely to become licensed are reviewed and the potential economic impact is discussed. Those drugs currently available, and those in development, may offer effective treatment for some of the core symptoms of AD, slowing the rate of cognitive decline and preserving competence in activities of daily living (ADLs) for longer. If handled correctly, these treatment have the potential to offer cost savings for many patients and cost-effectiveness improvements look probable. (AKM). |
| Accession Number | CPA-981013404 A |
| Classmark | EA: LLD: QDC: 8 |
Data © Centre for Policy on Ageing |
|
| ...from the Ageinfo database published by Centre for Policy on Ageing. |
| |
|